Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) is pleased to announce the first overseas surgery (robot-assisted radical prostatectomy) using the “hinotori™ Surgical Robot System” (hinotori™) was successfully performed at Singapore General Hospital.

In recent years, laparoscopic surgery, a minimally invasive procedure aimed at reducing the physical burden on patients, has been increasingly performed. The demand for surgical robots that support more precise procedures has been growing, and they are being utilized across a wide range of medical specialties. It is anticipated that the global market size for surgical robots will continue to expand in response to the increasing worldwide demand.

In August 2020, Medicaroid Corporation (HQ: Kobe, Japan; Board Director, CEO and President: Koji Muneto, hereinafter “Medicaroid”) obtained manufacturing and marketing approval in Japan for the hinotori™, a made-in-Japan robotic-assisted surgery system. In December of that same year, Sysmex, the global distributor for hinotori™, began its sales in the domestic market. The medical specialties eligible for insurance reimbursement have expanded from urology in 2020 to include gastrointestinal surgery and gynecology in 2022, and thoracic surgery (respiratory surgery) in 2024. As a result, the sales and installation of hinotori™ in Japan are progressing.

As a first step in global expansion Medicaroid obtained regulatory approval for hinotori™ in Singapore in September 2023 and in Malaysia in August 2024.

Since obtaining regulatory approval in Singapore, Sysmex has been working together with Medicaroid to establish a sales and service structure in preparation for the first overseas market introduction. We have completed the installation of a clinical-use hinotori™ at Singapore General Hospital, and the first overseas surgery (robot-assisted radical prostatectomy) has been performed.

Sysmex aims to contribute to a safer and more efficient surgical environment by providing hinotori™, which helps reduce the physical burden on patients. Through this, we strive to enhance the healthcare journey for individuals.

Terminology

*　hinotori™ is a registered trademark of Medicaroid Corporation

This press release is intended to inform our stakeholders about our corporate activities. It may include information about our products and research & development, but it is not intended for product promotion, advertising, or providing medical advice. Please note that the information contained herein is current as of the date of the announcement and is subject to change without notice.